- Acutus Medical (NASDAQ:AFIB) announces initial U.S. enrollments in the company’s AcQForce Flutter Investigational Device Exemption clinical trial.
- This trial is expected to enroll up to 150 subjects and will evaluate the safety and efficacy of the AcQBlate FORCE sensing ablation catheter and system in the treatment of Right Atrial Typical Flutter.
- In contrast to the most contemporary ablation systems, AcQBlate FORCE can operate both in a stand-alone manner or in conjunction with a compatible 3D mapping system.
- The AcQBlate FORCE sensing ablation catheter provides stable contact force readings with low fluid irrigation requirements. It displayed both easy maneuverability and excellent stability during atrial ablation.